Benchmark Financial Wealth Advisors LLC Has $1.13 Million Position in Bristol Myers Squibb Company $BMY

Benchmark Financial Wealth Advisors LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,500 shares of the biopharmaceutical company’s stock after acquiring an additional 1,934 shares during the period. Benchmark Financial Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in BMY. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Bristol Myers Squibb during the first quarter worth $31,000. Trifecta Capital Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Accent Capital Management LLC acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth $33,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new stake in Bristol Myers Squibb in the first quarter valued at about $36,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 1.0%

NYSE:BMY opened at $46.10 on Monday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company has a market cap of $93.82 billion, a PE ratio of 18.59, a P/E/G ratio of 2.23 and a beta of 0.33. The firm’s 50 day simple moving average is $45.34 and its 200 day simple moving average is $46.78.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.4%. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BMY. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $57.23.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.